104 related articles for article (PubMed ID: 38847938)
1. High malignancy rate in the absence of viral prophylaxis after kidney transplantation in Sudan.
Elamin S; Ibrahim SS; Mudawi H; Ali SEAM; Abdel-Satir A; Foad AFA
J Nephrol; 2024 Jun; ():. PubMed ID: 38847938
[TBL] [Abstract][Full Text] [Related]
2. The previously common post-kidney transplant Kaposi sarcoma has become non-existent for a decade: an Egyptian experience.
Donia AF; Fouda MA; Ghoneim ME; Refaie AF; Ali-El-Dein B
J Cancer Res Clin Oncol; 2021 May; 147(5):1493-1498. PubMed ID: 33130940
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Trial of Valganciclovir Prophylaxis Versus Preemptive Therapy in Kidney Transplant Recipients.
Reischig T; Vlas T; Kacer M; Pivovarcikova K; Lysak D; Nemcova J; Drenko P; Machova J; Bouda M; Sedivcova M; Kormunda S
J Am Soc Nephrol; 2023 May; 34(5):920-934. PubMed ID: 36749127
[TBL] [Abstract][Full Text] [Related]
4. Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis.
Opelz G; Daniel V; Naujokat C; Fickenscher H; Döhler B
Lancet Oncol; 2007 Mar; 8(3):212-8. PubMed ID: 17329191
[TBL] [Abstract][Full Text] [Related]
5. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
Jain A; Orloff M; Kashyap R; Lansing K; Betts R; Mohanka R; Menegus M; Ryan C; Bozorgzadeh A
Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
[TBL] [Abstract][Full Text] [Related]
6. Cytomegalovirus and Epstein-Barr virus infections among pediatric kidney transplant recipients at a center using universal Valganciclovir Prophylaxis.
Paulsen G; Cumagun P; Mixon E; Fowler K; Feig D; Shimamura M
Pediatr Transplant; 2019 May; 23(3):e13382. PubMed ID: 30786115
[TBL] [Abstract][Full Text] [Related]
7. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
8. Increased risk of breakthrough infection among cytomegalovirus donor-positive/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis.
Stevens DR; Sawinski D; Blumberg E; Galanakis N; Bloom RD; Trofe-Clark J
Transpl Infect Dis; 2015 Apr; 17(2):163-73. PubMed ID: 25661673
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
[TBL] [Abstract][Full Text] [Related]
10. Valganciclovir is not associated with decreased EBV infection rate in pediatric kidney transplantation.
Cheyssac E; Savadogo H; Lagoutte N; Baudouin V; Charbit M; Novo R; Sellier-Leclerc AL; Fila M; Decramer S; Merieau E; Zaloszyc A; Harambat J; Roussey G
Front Pediatr; 2022; 10():1085101. PubMed ID: 36704127
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of valganciclovir for prevention of infections with cytomegalovirus and Epstein-Barr virus after kidney transplant in children.
Cameron BM; Kennedy SE; Rawlinson WD; Mackie FE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27704725
[TBL] [Abstract][Full Text] [Related]
12. The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis.
Räihä J; Ortiz F; Mannonen L; Loginov R; Lempinen M; Lautenschlager I; Helanterä I
Transpl Infect Dis; 2021 Aug; 23(4):e13577. PubMed ID: 33527660
[TBL] [Abstract][Full Text] [Related]
13. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients.
Doesch AO; Repp J; Hofmann N; Erbel C; Frankenstein L; Gleissner CA; Schmidt C; Ruhparwar A; Zugck C; Schnitzler P; Ehlermann P; Dengler TJ; Katus HA
Drug Des Devel Ther; 2012; 6():289-95. PubMed ID: 23091373
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus infection in high-risk kidney transplant recipients receiving thymoglobulin induction-a single-center experience.
Puttarajappa C; Bhattarai M; Mour G; Shen C; Sood P; Mehta R; Shah N; Tevar AD; Humar A; Wu C; Hariharan S
Clin Transplant; 2016 Sep; 30(9):1159-64. PubMed ID: 27423138
[TBL] [Abstract][Full Text] [Related]
16. Incidence and management of Kaposi sarcoma in renal transplant recipients: the Greek experience.
Zavos G; Moris D; Vernadakis S; Bokos J; Lionaki S; Mamarelis G; Panagiotellis K; Zavvos V; Boletis I
Transplant Proc; 2014 Nov; 46(9):3199-202. PubMed ID: 25420858
[TBL] [Abstract][Full Text] [Related]
17. Primary effusion lymphoma occurring in the setting of transplanted patients: a systematic review of a rare, life-threatening post-transplantation occurrence.
Zanelli M; Sanguedolce F; Zizzo M; Palicelli A; Bassi MC; Santandrea G; Martino G; Soriano A; Caprera C; Corsi M; Ricci S; Ricci L; Ascani S
BMC Cancer; 2021 Apr; 21(1):468. PubMed ID: 33906629
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus prophylaxis with valganciclovir in African-American renal allograft recipients based on donor/recipient serostatus.
Gruber SA; Garnick J; Morawski K; Sillix DH; West MS; Granger DK; El-Amm JM; Alangaden GJ; Chandrasekar P; Haririan A
Clin Transplant; 2005 Apr; 19(2):273-8. PubMed ID: 15740567
[TBL] [Abstract][Full Text] [Related]
19. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Low-Dose Versus Standard-Dose Valganciclovir for Prevention of Cytomegalovirus Disease in Intermediate-Risk Kidney Transplant Recipients.
Halim MA; Al-Otaibi T; Gheith O; Adel H; Mosaad A; Hasaneen AA; Zakaria Z; Makkeya Y; Said T; Nair P
Exp Clin Transplant; 2016 Oct; 14(5):526-534. PubMed ID: 27310254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
